Prelude Therapeutics Incorporated (PRLD)

Profile

https://preludetx.com

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on discovering and developing novel medicines for cancer patients with high unmet medical needs. Prelude Therapeutics Incorporated is advancing a pipeline of targeted therapies designed to address genetically defined cancers and other difficult-to-treat tumors. Its current programs include small-molecule candidates aimed at key cancer-driving mechanisms such as JAK2V617F, KAT6A, and SMARCA2, as well as approaches for myeloproliferative neoplasms, myelofibrosis, polycythemia vera, essential thrombocythemia, and breast cancer. The company’s work centers on precision medicine, using selective drug design to improve specificity against validated oncology targets. Prelude Therapeutics Incorporated operates as part of the biotechnology sector and plays a role in translating molecular biology insights into potential treatment options for underserved cancer populations.